Integrating ferroptosis and the tumor-immune gene mutations interface: a novel lenvatinib resistance prognostic signature with YWHAB-related immunotherapeutic correlates in hepatocellular carcinoma
- 1Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University
- 2Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital
Abstract
Background: Lenvatinib resistance represents a major clinical challenge in the treatment of hepatocellular carcinoma (HCC), necessitating the identification of strategies to overcome this issue. Although ferroptosis, a non-apoptotic cell death process, is implicated in the progression of HCC and the response to lenvatinib, the prognostic relevance and the lenvatinib response-related mechanisms of ferroptosis-related genes (FRGs) remain poorly understood.
Methods: An eight-gene ferroptotic lenvatinib-related prognostic signature (FLRPS) was developed as a prognostic model. Based on the median risk score, the patients were classified into high-risk and low-risk groups to compare clinical outcomes, immune traits, and mutational profiles. Immunohistochemistry, spatial transcriptome analysis and single-cell RNA sequencing (scRNA-seq) were used to identify the specificity of YWHAB expression in HCC. In vitro and in vivo assays were utilized to evaluate the impact of YWHAB on the phenotypes of HCC cells and lenvatinib-induced ferroptosis, as well as to investigate the underlying mechanisms.
Results: The FLRPS, comprising eight genes (CENPA, RAN, CDCA8, KIF2C, YWHAB, HDAC2, DYNC1H1, and NRAS), yielded scores that positively correlated with poorer prognosis, advanced pathological grade, later clinical stage, metrics of genomic instability, and lower M2 macrophage infiltration. Furthermore, a nomogram integrating the FLRPS and tumor stage accurately predicted overall survival. Additionally, lenvatinib-resistant HCC samples exhibited elevated YWHAB expression. Downregulation of YWHAB sensitized Hepa1–6 cells to lenvatinib both in vitro and in vivo , an effect accompanied by decreased GPX4 levels and reversed by liproxstatin-1, suggesting a ferroptosis-related mechanism involving PI3K/AKT pathway inhibition.
Conclusions: The FLRPS serves as an effective predictive model for the prognosis of HCC. Targeting YWHAB may represent a promising therapeutic strategy to overcome lenvatinib resistance in HCC.
Related
- Cooperative inhibition of mTORC1 disrupts iron–redox homeostasis and triggers ferritinophagy-dependent ferroptosis in hepatocellular carcinoma
- Tumor-Associated Mast Cells Drive Immunosuppression and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4-mediated Regulatory T-Cell Recruitment.
- The role of insulin resistance in the development of hepatocellular carcinoma with computational analysis of IRS-1 interaction with HCV genotype 3 core protein
- A dual-host regulatory hub integrating biofilm formation and innate immunity resistance
- DREM: integrating resistance and domain probabilities to prioritize plant immune receptors
BibTeX
@article{yu2026integrating,
title = {{Integrating ferroptosis and the tumor-immune gene mutations interface: a novel lenvatinib resistance prognostic signature with YWHAB-related immunotherapeutic correlates in hepatocellular carcinoma}},
author = {Hang Yu and Zhihui Wang and Hongliang Zou and Haikuan Liu and Yujie Ma and Baoshan Cao and Jie Wen and Abudureyimujiang Aili},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1913042},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1913042/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrating ferroptosis and the tumor-immune gene mutations interface: a novel lenvatinib resistance prognostic signature with YWHAB-related immunotherapeutic correlates in hepatocellular carcinoma
AU - Hang Yu
AU - Zhihui Wang
AU - Hongliang Zou
AU - Haikuan Liu
AU - Yujie Ma
AU - Baoshan Cao
AU - Jie Wen
AU - Abudureyimujiang Aili
PY - 2026
DA - 2026/10/29
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1913042
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1913042/full
AB - Background: Lenvatinib resistance represents a major clinical challenge in the treatment of hepatocellular carcinoma (HCC), necessitating the identification of strategies to overcome this issue. Although ferroptosis, a non-apoptotic cell death process, is implicated in the progression of HCC and the response to lenvatinib, the prognostic relevance and the lenvatinib response-related mechanisms of ferroptosis-related genes (FRGs) remain poorly understood. Methods: An eight-gene ferroptotic lenvatinib-related prognostic signature (FLRPS) was developed as a prognostic model. Based on the median risk score, the patients were classified into high-risk and low-risk groups to compare clinical outcomes, immune traits, and mutational profiles. Immunohistochemistry, spatial transcriptome analysis and single-cell RNA sequencing (scRNA-seq) were used to identify the specificity of YWHAB expression in HCC. In vitro and in vivo assays were utilized to evaluate the impact of YWHAB on the phenotypes of HCC cells and lenvatinib-induced ferroptosis, as well as to investigate the underlying mechanisms. Results: The FLRPS, comprising eight genes (CENPA, RAN, CDCA8, KIF2C, YWHAB, HDAC2, DYNC1H1, and NRAS), yielded scores that positively correlated with poorer prognosis, advanced pathological grade, later clinical stage, metrics of genomic instability, and lower M2 macrophage infiltration. Furthermore, a nomogram integrating the FLRPS and tumor stage accurately predicted overall survival. Additionally, lenvatinib-resistant HCC samples exhibited elevated YWHAB expression. Downregulation of YWHAB sensitized Hepa1–6 cells to lenvatinib both in vitro and in vivo , an effect accompanied by decreased GPX4 levels and reversed by liproxstatin-1, suggesting a ferroptosis-related mechanism involving PI3K/AKT pathway inhibition. Conclusions: The FLRPS serves as an effective predictive model for the prognosis of HCC. Targeting YWHAB may represent a promising therapeutic strategy to overcome lenvatinib resistance in HCC.
SN - 1664-3224
ER -